Brokers Offer Predictions for Atossa Genetics Q1 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Investment analysts at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for Atossa Genetics in a report issued on Thursday, March 26th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($1.34) for the quarter, down from their prior forecast of ($1.20). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Atossa Genetics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Genetics’ Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.03) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.40) EPS and FY2029 earnings at ($0.20) EPS.

ATOS has been the topic of a number of other research reports. Ascendiant Capital Markets upped their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $68.33.

Atossa Genetics Price Performance

Shares of ATOS stock opened at $4.72 on Monday. Atossa Genetics has a one year low of $3.76 and a one year high of $19.35. The stock has a fifty day moving average price of $5.71 and a 200 day moving average price of $9.90. The stock has a market cap of $40.64 million, a P/E ratio of -1.31 and a beta of 1.42.

Institutional Investors Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in Atossa Genetics by 51.3% in the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after purchasing an additional 37,809 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in shares of Atossa Genetics by 357.4% in the second quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after buying an additional 325,340 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Atossa Genetics in the second quarter valued at $381,000. Ameriprise Financial Inc. acquired a new position in Atossa Genetics during the 2nd quarter worth about $2,468,000. Finally, Hudson Bay Capital Management LP acquired a new position in Atossa Genetics during the 2nd quarter worth about $26,000. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Genetics News Summary

Here are the key news stories impacting Atossa Genetics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $25 price target, giving investors a clear upside thesis that can support the stock. Article Title
• Positive Sentiment: The analyst substantially improved long‑range loss estimates (FY2027–FY2029 and into FY2030), trimming multi‑year projected losses and signaling a path toward much smaller deficits in later years — a development that can boost investor sentiment around potential recovery/value. Article Title
• Positive Sentiment: HC Wainwright raised several quarter estimates (notably Q3 and Q4 2026 and overall FY2026 modestly improved versus their prior view), which trims some near‑term downside in forecasts and supports a less bearish intermediate outlook.
• Neutral Sentiment: Consensus remains negative on GAAP EPS over the next few years and the company is still early in its development stage — the analyst changes reduce but do not eliminate structural risk; this is a high‑volatility, binary biotech exposure.
• Negative Sentiment: HC Wainwright increased near‑term quarterly loss estimates for Q1 and Q2 2026 (worse EPS for those quarters), and FY2026 still projects a sizable loss (~($4.75) per share), underscoring short‑term cash burn and execution risk that could pressure the stock if clinical or financing milestones slip.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.